181 related articles for article (PubMed ID: 25374001)
21. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
Choi JE; Kang SH; Lee SJ; Bae YK
Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
[TBL] [Abstract][Full Text] [Related]
22. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Davis AA; Gradishar WJ
Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
[TBL] [Abstract][Full Text] [Related]
23. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
24. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
25. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
[TBL] [Abstract][Full Text] [Related]
26. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
27. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.
Kim JY; Jung HH; Ahn S; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Sci Rep; 2016 Aug; 6():31804. PubMed ID: 27545642
[TBL] [Abstract][Full Text] [Related]
28. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
29. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
[TBL] [Abstract][Full Text] [Related]
30. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
Liedtke C; Rody A
Rev Recent Clin Trials; 2017; 12(2):73-80. PubMed ID: 28270088
[TBL] [Abstract][Full Text] [Related]
32. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
33. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
34. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM
Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430
[TBL] [Abstract][Full Text] [Related]
35. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
37. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
38. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
40. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.
O'Hurley G; Daly E; O'Grady A; Cummins R; Quinn C; Flanagan L; Pierce A; Fan Y; Lynn MA; Rafferty M; Fitzgerald D; Pontén F; Duffy MJ; Jirström K; Kay EW; Gallagher WM
Histopathology; 2014 Apr; 64(5):660-70. PubMed ID: 24138071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
